Catherine London, who has more than two decades of experience in the pharma and healthcare sectors, has joined biOasis Technologies as executive VP-corporate affairs and IR. She reports to CEO Mark Day.
|
|
Catherine LondonMost recently, London did a two-year stint as corporate communications chief at Purdue Pharma, maker of Oxycontin.
Earlier, she held corporate and product PR positions at Alexion Pharmaceuticals and Boehringer Ingelheim and worked at communications firms Chandler Chicco and Ruder Finn.
At biOasis, London assumes a newly created post in charge of external communications, visibility, brand-building and financial communications.
CEO Day praised London as a “forward-thinking communications leader and collaborative relationship builder.”
biOasis, which is based in Vancouver, has developed treatments for neurological diseases such as brain cancers, neurodegenerative and metabolic diseases.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
April is National Minority Health Month, spotlighting the urgency to improve health outcomes in communities of color.
In a recent conversation about the evolving media landscape, Doug Simon, CEO of D S Simon Media, spoke with Campbell O’Connor, Group Director, Media & Engagement at Real Chemistry, about how AI is influencing media relations and healthcare communications.
